• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    89Bio Inc (NQ: ETNB )

    8.915 -0.135 (-1.49%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about 89Bio Inc

    < Previous 1 2 3 Next >
    89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
    From 89bio, Inc.
    Via GlobeNewswire
    89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Participate in the UBS Global Healthcare Conference
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Participate in Upcoming Investor Conferences
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Appoints Francis Sarena as Chief Operating Officer
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
    -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- 
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Participate in the BofA Securities 2024 Health Care Conference
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
    Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET 
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Participate in the Leerink Partners Global Biopharma Conference
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From 89bio, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.